Psychopharmacology for the Clinician
The information in this column is not intended as a definitive treatment strategy but as a suggested approach for clinicians treating patientswith similar histories. Individual cases may vary and should be evaluated carefully before treatment is provided. The patient described in thiscolumn is a composite with characteristics of several real patients. Off-label antipsychotic use and tardive
dyskinesia in at-risk popu lations: new
drugs with old side effects
over the years, with limited response.
anxiety, led to an antipsychotic trial.
in off-label antipsychotic use across all age groups,1–5 perhaps reflecting their reputation. In addition, the field is sanc- fect. In the second year of treatment, he were initially attributed to on going den- with the atypical antipsychotics,9–11 all tients, 2 populations particularly sensi- part of our clinical decision-making.
Gary Remington, MD, PhD
Margaret Hahn, MD, PhD

abuse, race, sex and genetics.11–15 There Centre for Addiction and Mental Health and to schizophrenia itself.16–19 Studies Competing interests: Both authors declare
also declares consulting fees from Roche, chroneron and grants from Neurocrine andMedicure.
ments (i.e., localized, perioral). Within Psychopharmacology for the Clinician columns are usually based on a case report that illustrates a point of interest in clinical psychopharma-cology. They are about 650 words long. Columns can include a bibliography which will be available only onthe journal website. J Psychiatry Neurosci 2014;39(1)
Off-label antipsychotic use and tardive dyskinesia ment. Int Rev Neurobiol 2011;98:187-210.
a systematic review of 1-year studies.
Am J Psychiatry 2004;161:414-25.
schizophrenia: relationship of ‘tardive’ A, et al. Increasing off-label use of an- nesia and new antipsychotics. Curr Opin and negative symptoms. Br J Psychiatry States, 1995-2008. Pharmacoepidemiol Wade JB, Taylor MA, Kasprisin A, et al.
pairment. Biol Psychiatry 1987;22:393-5.
Psychiatr Serv 2008;59:507-14.
editors. Handbook of Clinical Neurology: Hyperkinetic Movement Disorders. New medication use in Australia 2002-2007.
Aust N Z J Psychiatry 2010;44:372-7.
Jeste DV, Caligiuri MP, Paulsen JS, et al.
study. J Clin Psychiatry 2010;71:463-74.
of atypical antipsychotics: cause for con- cern? CNS Drugs 2012;26:383-90.
of 266 outpatients. Arch Gen Psychiatry hyperkinetic movement disorders. Am J Geriatr Pharmacother 2010;8:331-73.
Bhidayasiri R, Fahn S, Weiner WJ, et al.
prevalence and risk factors, 1959 to 1979.
adults with antipsychotics. Arch Gen Arch Gen Psychiatry 1982;39:473-81.
Crystal S, Olfson M, Huang C, et al.
dyskinesia. Int Rev Neurobiol 2011;98: chotics: safety, effectiveness, and policy Miller DD, McEvoy JP, Davis SM, et al.
Clinical correlates of tardive dyskinesia min E supplementation? Crit Rev Food CATIE schizophrenia trial. Schizophr Res Caroff SN, Davis VG, Miller DD, et al.
chotics: rethinking “off-label”. Psychiatr nia. J Clin Psychiatry 2011;72:295-303.
schizophrenia. Acta Psychiatr Scand view. CNS Drugs 2005;19(Suppl 1):1-93.
recognition and management. Postgrad dyskinesia: clinical presentation and treat- J Psychiatry Neurosci 2014;39(1)


WHO Europe evidence based recommendations on thetreatment of tobacco dependenceM Raw, P Anderson, A Batra, G Dubois, P Harrington, A Hirsch, J Le Houezec,A McNeill, D Milner, M Poetschke Langer, W Zatonski—Recommendations panel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Adrenoreceptors and bc - may 2010

Adrenoceptors and breast cancer: Review article Roisman R., Klemm O., Raphaeli G., and Roisman I. Dedicated to Mrs. Minka Klavins and Prof. Janis V. Klavins Albert Einstein College of Medicine, New York, NY, USA Correspondence to: Isaac Roisman, M.D., Dip. Surg., M. Surg., D.Sc. P.O.Box 45470 , Haifa 31453, Israel Tel.: (972-4)8388393, Fax: (972-4)8379503 Adrenocepto

© 2010-2018 Modern Medicine